Magaldrate: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Magaldrate": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 43: Line 43:
| molecular_weight = 212.66 g/mol
| molecular_weight = 212.66 g/mol
}}
}}
 
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
 
'''Magaldrate''' ([[International Nonproprietary Name|INN]]) is a common [[antacid]] [[Medication|drug]] that is used for the treatment of [[duodenal]] and [[gastric ulcer]]s, [[esophagitis]] from [[gastroesophageal reflux]].
'''Magaldrate''' ([[International Nonproprietary Name|INN]]) is a common [[antacid]] [[Medication|drug]] that is used for the treatment of [[duodenal]] and [[gastric ulcer]]s, [[esophagitis]] from [[gastroesophageal reflux]].


Line 59: Line 63:


==References==
==References==
{{Refimprove|date=September 2014}}
 
{{reflist}}
{{reflist|2}}


{{Antacids}}
{{Antacids}}


[[Category:Aluminates]]
[[Category:Drug]]
[[Category:Magnesium compounds]]
[[Category:Magnesium compounds]]




{{gastrointestinal-drug-stub}}
{{gastrointestinal-drug-stub}}

Latest revision as of 16:38, 20 August 2015

Magaldrate
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682683
Pregnancy
category
  • C
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNegligible
MetabolismNil
ExcretionFecal and renal
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaAlMg2(OH)7·H2O
Molar mass212.66 g/mol
  (verify)

WikiDoc Resources for Magaldrate

Articles

Most recent articles on Magaldrate

Most cited articles on Magaldrate

Review articles on Magaldrate

Articles on Magaldrate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Magaldrate

Images of Magaldrate

Photos of Magaldrate

Podcasts & MP3s on Magaldrate

Videos on Magaldrate

Evidence Based Medicine

Cochrane Collaboration on Magaldrate

Bandolier on Magaldrate

TRIP on Magaldrate

Clinical Trials

Ongoing Trials on Magaldrate at Clinical Trials.gov

Trial results on Magaldrate

Clinical Trials on Magaldrate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Magaldrate

NICE Guidance on Magaldrate

NHS PRODIGY Guidance

FDA on Magaldrate

CDC on Magaldrate

Books

Books on Magaldrate

News

Magaldrate in the news

Be alerted to news on Magaldrate

News trends on Magaldrate

Commentary

Blogs on Magaldrate

Definitions

Definitions of Magaldrate

Patient Resources / Community

Patient resources on Magaldrate

Discussion groups on Magaldrate

Patient Handouts on Magaldrate

Directions to Hospitals Treating Magaldrate

Risk calculators and risk factors for Magaldrate

Healthcare Provider Resources

Symptoms of Magaldrate

Causes & Risk Factors for Magaldrate

Diagnostic studies for Magaldrate

Treatment of Magaldrate

Continuing Medical Education (CME)

CME Programs on Magaldrate

International

Magaldrate en Espanol

Magaldrate en Francais

Business

Magaldrate in the Marketplace

Patents on Magaldrate

Experimental / Informatics

List of terms related to Magaldrate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Available forms

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[1]

Interactions and adverse reactions

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.

Brand names

The drug is sold with the following brand names: Digecid Plus (Beximco Pharma, Bangladesh), Marlox Plus (Incepta pharma Bangladesh), Gastid (SK+F, Bangladesh), Novelta (Bangladesh), Gadral (Italy); Magaltop (Italy); Magralibi (Italy); Mylanta (Australia); Riopan (Argentina, Austria, Brazil, Egypt, Germany, Italy, Mexico, Belgium, Switzerland, Greece).

References

  1. Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.

Template:Antacids


Template:Gastrointestinal-drug-stub